Photocure ASA

Earnings Release • Dec 14, 2015

Photocure: Visonac® data published in the British Journal of Dermatology

Photocure: Visonac® data published in the British Journal of Dermatology

Phase 2b results demonstrate a significant reduction in inflammatory lesions and

a significant improvement in overall acne severity

Oslo, Norway, December 14, 2015: Photocure (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, announces the publication of the results from the Phase 2b trial of

Visonac (methyl aminolevulinate 80mg/g), a novel topical acne treatment, in the

British Journal of Dermatology.

The Phase 2b trial was a multicenter, randomized, double-blind, placebo

controlled study in patients with severe acne vulgaris. Results showed Visonac®

produced a statistically significant reduction in inflammatory lesions and an

overall improvement in acne severity.

Dr David Pariser, Professor of Dermatology, Eastern Virginia Medical School,

former president of the American Academy of Dermatology and principal

investigator, commented: "These data are promising as they demonstrate Visonac's

potential as a significant advancement in the treatment of acne patients. There

is a high unmet medical need for novel, non-antibiotic alternative treatment

options in this patient population in whom the presence of multiple inflammatory

lesions takes a high toll on both their emotional and social well-being."

The study included 153 patients enrolled at 15 office-based dermatology

practices and hospitals in the US.  In patients treated with Visonac, a

statistically significant reduction in inflammatory acne lesions of 43.8% was

achieved compared to 26.6% in the control group (p=0.003). Visonac also

demonstrated improvement in overall acne severity in a significant percentage of

patients as compared to control, 44.0%  versus 26.4% (p=0.013), respectively.

Visonac was well tolerated and no serious adverse events were reported in the

study.

Kjetil Hestdal, President and CEO of Photocure, said: "We are pleased to see

this data published in such an esteemed journal, and view this as a testament to

the potential of Visonac as a new treatment option for the large number of

patients globally who suffer from severe acne. Visonac's high level of efficacy

coupled with the high patient tolerability demonstrated in the Phase 2b trial

are encouraging, and will aid in advancing to the next stage of development."

The full publication of the results from the Visonac phase 2b study, originally

completed in 2012, is available through the online publication in The British

Journal of Dermatology, "Photodynamic therapy with 80mg/g metyl aminolaevulinate

for severe facial acne vulgaris: a randomized vehicle-controlled study" at

http://onlinelibrary.wiley.com/doi/10.1111/bjd.14345/epdf

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 450 55 000, Email: ed@photocure.no

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(®) platform, Photocure develops and

commercializes highly selective and effective solutions in disease areas with

high unmet medical need, such as bladder cancer, HPV and precancerous cervical

lesions, colorectal cancer and skin conditions. Our aim is to provide solutions

that can improve health outcomes for patients worldwide. Photocure is listed on

the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com.

About Visonac

Acne is the single most common skin disease worldwide, and affects up to 85% of

all 12-24 year olds. There is a high unmet medical need for patients with acne,

where the current mainstay of treatment is oral antibiotics and/or retinoids.

Visonac is being developed as the first photodynamic therapeutic option for this

large patient population, which can easily and conveniently be administered in

dermatology offices. By avoiding the risks of increased antibiotic resistance

from long term exposure, and providing a highly tolerable alternative to

isotretinoin, Visonac has the potential to satisfy a high unmet medical need.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1973180]